These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2227073)

  • 61. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
    Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
    Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Study of the bioavailability of drugs with a cyclandelate base].
    Andermann G; Dietz M; Mergel D
    Pharm Acta Helv; 1979; 54(12):366-9. PubMed ID: 583451
    [No Abstract]   [Full Text] [Related]  

  • 63. [Determination of free and conjugated cis-3,3,5-trimethylcyclohexanol in plasma and urine].
    Andermann G; Dietz M
    J Chromatogr; 1983 Feb; 272(2):299-305. PubMed ID: 6833426
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibitory action of cyclandelate and a number of its metabolites on cyclic AMP phosphodiesterase.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():20-5. PubMed ID: 6331483
    [No Abstract]   [Full Text] [Related]  

  • 65. The effect of cyclandelate on cholesterol synthesis.
    Middleton B; Middleton A; Miciak A; Edwards E; Whitten B; Bell GD; White DA
    Br J Clin Pract Suppl; 1984; 34():43-50. PubMed ID: 6430323
    [No Abstract]   [Full Text] [Related]  

  • 66. The melting-point of cyclospasmol and the quantitative determination of small amounts of 3.5.5.-trimethylcyclohexyl phenylglyoxylate in same.
    REKKER RF; ERNSTING MJ; NAUTA WT
    Pharm Weekbl; 1956 Jan; 91(1):1-6. PubMed ID: 13310216
    [No Abstract]   [Full Text] [Related]  

  • 67. Bioavailability of cyclandelate from capsules in beagle dogs and dissolution rate: correlations with bioavailability in humans.
    Kaniwa N; Ogata H; Aoyagi N; Ejima A; Takahashi T; Uezono Y; Imasato Y
    J Pharmacobiodyn; 1991 Mar; 14(3):152-60. PubMed ID: 1880705
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Distribution of tritiated cyclandelate (3,5,5-trimethylcyclohexyl mandelate)-a vasoactive drug: preliminary observations by liquid scintillation spectrometry.
    Orr A; Whittier JR
    Int J Nucl Med Biol; 1974 Jun; 1(4):205-13. PubMed ID: 4435997
    [No Abstract]   [Full Text] [Related]  

  • 69. Treatment of the cerebral manifestations of arteriosclerosis with cyclandelate.
    Young J; Hall P; Blakemore C
    Br J Psychiatry; 1974 Feb; 124(579):177-80. PubMed ID: 4596673
    [No Abstract]   [Full Text] [Related]  

  • 70. Cyclandelate in the prophylaxis of migraine: a placebo-controlled study.
    Diener HC; Krupp P; Schmitt T; Steitz G; Milde K; Freytag S
    Cephalalgia; 2001 Feb; 21(1):66-70. PubMed ID: 11298666
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and tolerance of cyclandelate versus pizotifen in the prophylaxis of migraine.
    Mastrosimone F; Iaccarino C; de Caterina G
    J Med; 1992; 23(1):1-16. PubMed ID: 1573338
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Vasodilator drugs in peripheral vascular disease.
    Coffman JD
    Am J Hosp Pharm; 1975 Dec; 32(12):1276-81. PubMed ID: 1108646
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cyclandelate in the management of tinnitus: a randomized, placebo-controlled study.
    Hester TO; Theilman G; Green W; Jones RO
    Otolaryngol Head Neck Surg; 1998 Mar; 118(3 Pt 1):329-32. PubMed ID: 9527112
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effect of cyclandelate on mental function in patients with arteriosclerotic brain disease.
    Fine EW; Lewis D; Villa-Landa I; Blakemore CB
    Br J Psychiatry; 1970 Aug; 117(537):157-61. PubMed ID: 4921174
    [No Abstract]   [Full Text] [Related]  

  • 75. Drug therapy: vasodilator drugs in peripheral vascular disease.
    Coffman JD
    N Engl J Med; 1979 Mar; 300(13):713-7. PubMed ID: 368637
    [No Abstract]   [Full Text] [Related]  

  • 76. Vasodilator drugs in peripheral vascular disease.
    Coffman JD
    J Maine Med Assoc; 1975 Oct; 66(10):262-9. PubMed ID: 1104731
    [No Abstract]   [Full Text] [Related]  

  • 77. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. The Study group.
    Diener HC; Föh M; Iaccarino C; Wessely P; Isler H; Strenge H; Fischer M; Wedekind W; Taneri Z
    Cephalalgia; 1996 Oct; 16(6):441-7. PubMed ID: 8902255
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers.
    Hughes KM; Lang JC; Lazare R; Gordon D; Stanton SL; Malone-Lee J; Geraint M
    Xenobiotica; 1992 Jul; 22(7):859-69. PubMed ID: 1455904
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Enantiomeric separation of mandelic acid and its analogues by high performance liquid chromatography with 2,6-di-O-pentyl-beta-cyclodextrin coated symmetry C8 column].
    Ruan Y; Zhang X; Chen A; Qiu H; Huang P
    Se Pu; 2004 Jul; 22(4):420-3. PubMed ID: 15709424
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cyclandelate versus propranolol in the prophylaxis of migraine--a double-blind placebo-controlled study.
    Gerber WD; Schellenberg R; Thom M; Haufe C; Bölsche F; Wedekind W; Niederberger U; Soyka D
    Funct Neurol; 1995; 10(1):27-35. PubMed ID: 7649498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.